|
|
|
| Research progress of severe acute respiratory syndrome, Middle East respiratory syndrome and corona virus disease 2019 treatment |
| FU Zhangfan, AI Jingwen |
| Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, China |
|
|
|
|
Abstract Severe acute respiratory syndrome (sever acute respiratory syndrome, SARS), Middle East respiratory syndrome (middle east respiratory syndrome, MERS), and new coronavirus pneumonia (corona virus disease 2019, COVID-19) have brought serious illnesses to people all over the world. Economic loss and mental injury, given that there are no new cases of SARS and little progress in research, this article focuses on the treatment of MERS and COVID-19. The treatments of MERS and COVID-19 are similar. Nucleoside analogs, lopinavir/ritonavir, neutralizing antibodies, glucocorticoids, and other potential therapies (new use of old drugs) have been used clinically. Due to the wide spread of COVID-19 and the large number of infected people, some new drugs have emerged, such as Remdesivir, REGN-COV2 antibody, LY-CoV555 antibody, etc., but the current effect is not good, and the clinical diagnosis and treatment plan has yet to be improved. This article reviews the research progress in the treatment of SARS, MERS and COVID-19, and provides a theoretical basis for further research on their treatment options, improving treatment effects, and reducing mortality.
|
|
Received: 26 October 2020
Published: 25 June 2021
|
|
|
|
Corresponding Authors:
AI Jingwen
|
|
|
|
|
|
|
2021, Vol. 16 
